Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Comment by guildwood1on Mar 11, 2015 1:33pm
77 Views
Post# 23510164

RE:RE:RE:RE:I can't wait

RE:RE:RE:RE:I can't wait@InvertedHammer clearly you are a tool. Where did I say large companies only sign big dollar contracts?  

I said I wouldnt expect it to be a low dollar figure based on its a supply contract that doesnt mention a "pilot project" with a major US pharma company associated with a market leading ophthalmology product indicated for a variety of ophthalmic complications including diabetes.  

Clearly the potential size of that demographic in the US alone is a very large number client base and therefore would EXPECT a large revenue associated with that.  

Never even implied that large companies only sign big dollar contracts but I do know for a fact large companies do only sign contracts with respectable and established companies thus the validation to CARA's proficiency and potential.  

If there wasnt any benefit to this major pharma companies direction they wouldnt be interested. That is irrefutable.
Bullboard Posts